Annexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathway

Por Zhang, Shuang, Yu, Min, Guo, Qiang, Li, Rongpeng, Li, Guobo, Tan, Shirui, Li, Xuefeng, Wei, Yuquan, Wu, Min
Publicado no Sci Rep (2015)

YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models

Por Xu, Youzhi, Lin, Hongjun, Meng, Nana, Lu, Wenjie, Li, Guobo, Han, Yuanyuan, Dai, Xiaoyun, Xia, Yong, Song, Xiangrong, Yang, Shengyong, Wei, Yuquan, Yu, Luoting, Zhao, Yinglan
Publicado em 2013

A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

Por Xu, Youzhi, Lu, Wenjie, Yang, Peng, Peng, Wen, Wang, Chunting, Li, Manli, Li, Yan, Li, Guobo, Meng, Nana, Lin, Hongjun, Kan, Lixin, Wang, Siying, Yang, Shengyong, Yu, Luoting, Zhao, YingLan
Publicado no BMC Cancer (2015)

A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models

Por Zhang, Nannan, Zhang, Guo, Liu, Ning, Lin, Wanting, Ji, Sen, Zheng, Mingwu, Chen, Kai, Liang, Xiao, Li, Guobo, Ma, Yu, Zhu, Jun, Niu, Ting, Li, Lin-Li, Li, Jiong, Wei, Yu-Quan, Yang, Sheng-Yong
Publicado no Oncotarget (2017)

YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

Por Xia, Yong, Song, Xuejiao, Li, Deliang, Ye, Tinghong, Xu, Youzhi, Lin, Hongjun, Meng, Nana, Li, Guobo, Deng, Senyi, Zhang, Shuang, Liu, Li, Zhu, Yongxia, Zeng, Jun, Lei, Qian, Pan, Youli, Wei, Yuquan, Zhao, Yinglan, Yu, Luoting
Publicado em 2014